Print
20 April 2015
Michelle Dalton / Ophthalmology Times
San Diego—Study patients with a near vision inlay implanted under a femtosecond flap achieved extended depth of focus that ranged from +1 to +3 D, said John A. Hovanesian, MD.
Participants in the multicenter, prospective, FDA investigational device exemption study had to be emmetropic with presbyopia that required a reading add form +1.5 to +2 D, said Dr. Hovanesian, in practice in Laguna Hills, CA.
The implant (Raindrop Near Vision Inlay, ReVision Optics) is designed to change the curvature of the overlying cornea creating a gradient of power that allows a full range of uninterrupted vision.
“We implanted the inlay in the non-dominant eye, and concentrated this evaluation on a sub-group of 30 patients from two clinical sites,” he said.
Sub-study endpoints included defocus curves and contrast sensitivity measured preoperatively and 12 months postoperatively. Uncorrected and best-corrected visual acuity (UCVA and BCVA, respectively) were measured with the ETDRS charts and collected in the Optec Vision Tester (Stereo Optical Co.) at near (40 cm), intermediate (80 cm), and distance (6 m) at preoperatively, 1 week, 1 month, 3 months, and 12 months postoperatively. Defocus curves and contrast sensitivity were measured as part of a substudy at preoperatively and 12 months.
At 12 months (n = 30), monocular near and intermediate visual acuities improved from preoperative levels of 20/72 (uncorrected near visual acuity) to 20/22. Uncorrected intermediate visual acuity improved from 20/46 to 20/26, Dr. Hovanesian said.
Binocularly, all subjects were 20/32 or better at near, 20/32 or better at intermediate, and 20/20 or better at distance.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.